Ignite Creation Date:
2025-12-24 @ 4:02 PM
Ignite Modification Date:
2025-12-27 @ 9:31 PM
Study NCT ID:
NCT04478266
Status:
TERMINATED
Last Update Posted:
2025-09-11
First Post:
2020-07-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
Sponsor:
Sanofi
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
EFC15935
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None